Past, present and future targets for immunotherapy in ovarian cancer - Wikidata - wikimedia - TriplyDB

Past, present and future targets for immunotherapy in ovarian cancer

Past, present and future targets for immunotherapy in ovarian cancer

http://www.wikidata.org/entity/Q35034010

about

Adoptive immunotherapy against ovarian cancer Downregulation of SASH1 correlates with tumor progression and poor prognosis in ovarian carcinoma.Dihydromyricetin Induces Apoptosis and Reverses Drug Resistance in Ovarian Cancer Cells by p53-mediated Downregulation of Survivin Effect of targeted ovarian cancer immunotherapy using ovarian cancer stem cell vaccine.Induced Pluripotent Stem Cell-Derived Natural Killer Cells for Treatment of Ovarian Cancer.Expression of tumor antigens on primary ovarian cancer cells compared to established ovarian cancer cell lines.HM015k, a Novel Silybin Derivative, Multi-Targets Metastatic Ovarian Cancer Cells and Is Safe in Zebrafish Toxicity Studies Correlation Between Tumor Mesothelin Expression and Serum Mesothelin in Patients with Epithelial Ovarian Carcinoma: A Potential Noninvasive Biomarker for Mesothelin-targeted Therapy.Maintenance treatment with oral cyclophosphamide and bevacizumab in patients with recurrent epithelial ovarian cancer.Transcriptional profiling of NCI/ADR-RES cells unveils a complex network of signaling pathways and molecular mechanisms of drug resistance.Targeting Tumor Metabolism: A New Challenge to Improve Immunotherapy.

P2860

Q26748905-58E0C7F6-D33C-446C-80DE-0A6A2B9398E1 Q30008980-0322D628-97B2-4A1A-AD45-6E734F8DD74C Q33594379-8D1F1AC5-1099-48B1-9E38-2B79B92BF0E3 Q36204651-54604BA3-C0E5-4900-A446-81812663F376 Q36463830-DE901CEC-B476-4A52-9F5A-556DD03DAF2D Q37564665-BA46F34F-E5E5-4773-9B68-9F36310BC1D9 Q38639870-77817591-BB3E-4F82-8EE3-5EF198F3816C Q38761712-4B9D9970-4847-414D-A788-C6DC5F9F1498 Q38969949-597FF103-4758-47E4-91BC-2DD556B515ED Q49594024-25056F6C-51EA-44E1-AC90-872466CA9BA7 Q52661722-C72CA830-B7FE-4313-9274-060CC90B2F04

P2860

Past, present and future targets for immunotherapy in ovarian cancer

http://www.wikidata.org/entity/Q35034010

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Past, present and future targets for immunotherapy in ovarian cancer

@ast

Past, present and future targets for immunotherapy in ovarian cancer

@en

type

label

Past, present and future targets for immunotherapy in ovarian cancer

@ast

Past, present and future targets for immunotherapy in ovarian cancer

@en

prefLabel

Past, present and future targets for immunotherapy in ovarian cancer

@ast

Past, present and future targets for immunotherapy in ovarian cancer

@en

P1433

Q35034010-B1670254-8108-4D53-AACC-4483233BEF2B

P1476

Q35034010-55B7ED18-2FA5-4532-AA44-B07C609D9393

P2093

Q35034010-652C4C3F-B593-43AE-9B50-C3BF1EB5EA74

Q35034010-9AF7F74C-344A-4EFE-BE66-A9DF10F9D841

Q35034010-A8B66C25-DCC2-4C2F-B1E6-1C42551A57D7

Q35034010-DBAA43A1-86FE-42CA-BA33-618DA75C08EA

Q35034010-E4D854BA-1AAA-4D9F-9704-4E27C4F9E3C5

P2860

Q35034010-008FA8AA-6E29-4BCA-A37D-CF0F988C87DE

Q35034010-02D2DD46-822B-4B40-92EF-E257691B7C45

Q35034010-03EBDBBA-796F-43DF-B879-4B565EE249F3

Q35034010-06FCFE57-C5B6-47A1-9771-CFB6EB9BF914

Q35034010-08321FA5-5CC3-4CD9-A904-EDFF93587545

Q35034010-0BFEC9FA-003E-4D49-BADB-7F5AD73202E9

Q35034010-0CC9766C-5657-472C-8166-EABD6C112219

Q35034010-0D6B6D40-9741-4651-8057-6D3172D24EF9

Q35034010-0E0F34C5-CE1F-4815-9A1D-60CF66E56998

Q35034010-0E53F5A8-615A-4B62-9CF2-335F2752FF78

P304

Q35034010-8CCACA5D-CA80-4A38-878B-7338706F79FD

P31

Q35034010-60121B99-61C2-43FC-8192-D37CD85DBC59

P356

Q35034010-0FDF6309-7635-49BF-A9AD-86843DF2E56D

P433

Q35034010-F74903A3-7C25-4406-BC2C-EB183435EEF2

P478

Q35034010-445EFA65-2C0E-4B65-BEFB-58C9C5753467

P577

Q35034010-8F6DE20F-3207-402E-82D9-7E76008FC3B2

P698

Q35034010-E8197F10-3C4A-4854-85D5-7CEB3545F2BC

P921

Q35034010-C94E23BA-625F-4D3F-A11C-D1F8CFD67159

P932

Q35034010-88115058-C4C8-4231-90D1-7D1DF8CE22DA

P356

P1433

P1476

Past, present and future targets for immunotherapy in ovarian cancer

@en

P2093

Alessandro D Santin

http://www.w3.org/2001/XMLSchema#string

Carlton L Schwab

http://www.w3.org/2001/XMLSchema#string

Dana M Roque

http://www.w3.org/2001/XMLSchema#string

Diana P English

http://www.w3.org/2001/XMLSchema#string

Monica Pasternak

http://www.w3.org/2001/XMLSchema#string

P2860

Ovarian carcinoma subtypes are different diseases: implications for biomarker studies

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

Mesothelin targeted cancer immunotherapy

ICAM-1 regulates neutrophil adhesion and transcellular migration of TNF-alpha-activated vascular endothelium under flow

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

Continuous cultures of fused cells secreting antibody of predefined specificity

Antigen-specific immunotherapy of cervical and ovarian cancer

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

Integrated genomic analyses of ovarian carcinoma

P304

1279-1293

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/IMT.14.90

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25524384

http://www.w3.org/2001/XMLSchema#string

P921

P932

4312614

http://www.w3.org/2001/XMLSchema#string